During the COVID-19 pandemics the management of immunosuppressed patients, such as those affected by autoimmune bullous diseases (AIBDs), became a matter of particular concern for healthcare systems; dissemination of sound and updated information became mandatory to orient physicians and, more generally healthcare policy [1,2]. Furthermore, AIBDs patients were encouraged take advantage from teledermatological rather than in-person consultations; also, they were encouraged to undergo COVID-19 vaccination, preferably during remission periods or at least while under low immunosuppression [3,4].

The first dose of COVID‐19 vaccine may trigger pemphigus and bullous pemphigoid flares: is the second dose therefore contraindicated? / G. Damiani, A. Pacifico, F. Pelloni, M. Iorizzo. - In: JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. - ISSN 0926-9959. - (2021). [Epub ahead of print] [10.1111/jdv.17472]

The first dose of COVID‐19 vaccine may trigger pemphigus and bullous pemphigoid flares: is the second dose therefore contraindicated?

G. Damiani
Primo
Conceptualization
;
2021

Abstract

During the COVID-19 pandemics the management of immunosuppressed patients, such as those affected by autoimmune bullous diseases (AIBDs), became a matter of particular concern for healthcare systems; dissemination of sound and updated information became mandatory to orient physicians and, more generally healthcare policy [1,2]. Furthermore, AIBDs patients were encouraged take advantage from teledermatological rather than in-person consultations; also, they were encouraged to undergo COVID-19 vaccination, preferably during remission periods or at least while under low immunosuppression [3,4].
COVID-19 pandemic; COVID-19 vaccine; SARS-CoV-2; bullous pemphigoid; pemphigus; safety; teledermatology
Settore MED/35 - Malattie Cutanee e Veneree
25-giu-2021
Article (author)
File in questo prodotto:
File Dimensione Formato  
jdv.17472.pdf

embargo fino al 25/06/2022

Tipologia: Post-print, accepted manuscript ecc. (versione accettata dall'editore)
Dimensione 3.52 MB
Formato Adobe PDF
3.52 MB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2434/853816
Citazioni
  • ???jsp.display-item.citation.pmc??? 27
  • Scopus 35
  • ???jsp.display-item.citation.isi??? 35
social impact